News
NICE rejects Darzalex, citing lack of clinical evidence
NICE has rejected Janssen’s Darzalex (daratumumab) for regular NHS funding in third line multiple myeloma, saying that gaps in clinical evidence mean cost-effectiveness data are unreliable.
